TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +4.2%
- EBIT
- +6.3%
- EPS
- +27.0%
- Free cash flow
- +43.7%
- Operating cash flow
- +43.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +35.7%
- EBIT
- +36.8%
- Net income
- +37.2%
- EPS
- —
- Free cash flow
- +19.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026